help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
First published online on February 21, 2008
This version published online on May 12, 2008
Endocrine Reviews, doi:10.1210/er.2007-0031
Endocrine Reviews, doi:10.1210/er.2007-0031
Endocrine Reviews 0 (2008): 200700312-
Copyright © 2008 by The Endocrine Society
This Article
Right arrow Final Manuscript (PDF)
Right arrow RPHR Note
Right arrow All Versions of this Article:
29/3/367    most recent
Final Manuscript
Author Manuscript
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Salehi, M.
Right arrow Articles by D'Alessio, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salehi, M.
Right arrow Articles by D'Alessio, D. A.

Submitted on September 10, 2007
Accepted on January 25, 2008

Targeting {beta}-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins

Marzieh Salehi, Benedikt A. Aulinger, and David A. D'Alessio*

Department of Medicine, Division of Endocrinology, University of Cincinnati, Cincinnati, Ohio 45267-0547

* To whom correspondence should be addressed. E-mail: dalessd{at}ucmail.uc.edu.

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic {beta}-cells or a reduction in {beta}-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on {beta}-cell physiology as well as by expanding or at least maintaining {beta}-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society